RBM22

Across TCGA pan-cancer cohorts, RBM22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBM22 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher RBM22 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM22 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

COAD, ESCA, and SKCM are the cancer types where RBM22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.153	0.700	<.001	15	view →
ESCA	DFS	Median	All	0.098	0.533	.003	6	view →
SKCM	DFS	Median	II,III,IV	0.872	0.545	.035	4	view →
UCEC	DFS	Median	All	1.000	0.831	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBM22–COAD (DFS)

Open the COAD breakdown →